Erbitux Approval Expanded to Include Head and Neck Cancer (HealthDay)

Admin

Administrator
Staff member
HealthDay - MONDAY, Nov. 7 (HealthDay News) -- U.S. Food and Drug Administration approval of Erbitux (cetuximab) has been expanded to include late-stage (metastatic) head and neck cancer, the agency announced Monday.

More...
 
Top